CD8A and melanoma: reported that FMT combined with anti‐PD‐1 therapy benefits PD‐1‐refractory melanoma patients by inducing lasting microbiota changes, increasing CD8+ T cell activation, and reducing IL‐8+ myeloid cells, accompanied by distinct proteomic and metabolomic signatures.[297] Dizman et al.